Abstract:Abstract Introduction The disease burden of lymphoid neoplasm has been rising in China over the last decade. But most patients manifest with advanced stage disease at initial diagnosis, and the prognosis is poor with a 5-year survival rate of 38.3%. Here we reported a novel multivariate cancer risk score (CRS) model which is used to detect early lymphoid neoplasm from the peripheral blood. It incorporates three cancer hallmarks, copy number aberrations (CNA) and fragment size (FS) via shallow whole genome sequencing (sWGS) from cell-free DNA (cfDNA), and a panel of seven tumor protein markers in a single blood draw (10ml). Methods 44 newly diagnosed and untreated stage I-IV lymphoid neoplasm patients and 247 healthy individuals with no cancer diagnosis were enrolled in this study. 10ml peripheral blood was collected from each participant after enrollment. cfDNA was extracted and subjected to sWGS whereas plasma was subjected to measure the levels of 7 PTMs. The cancer risk score (CRS) of a subject was calculated via an established CRS model [1]. Results Firstly, genomic and epigenetic features were explored from cfDNA sWGS results. CNA is a ubiquitous genomic hallmark in a wide spectrum of cancers. In this study, 26 of the 44 (59.1%) lymphoid neoplasm patients had CNA in at least one genomic segment (>5Mb). FS feature of cfDNA bears the correspondence of the epigenetic landscapes of cells that give rise to those cfDNA fragments. When CNA was combined with FS, 29 (65.9%) patients were able to be detected by the CNA+FS classifier. On the other hand, 13 (29.5%) patients were tested positive by PTMs alone, indicating non-DNA molecular surrogates can also serve as cancer biomarkers with acceptable performance. When CNA, FS and PTM were incorporated into a multidimensional and multivariate CRS model, it achieved the best performance allowing 31 (70.0%) lymphoid neoplasm cases to be identified with a positive predictive value (PPV) of 86.1% at 98.0% specificity. The sensitivity of CRS model increases with the advances of disease with a sensitivity of 50.0% in early stage (stage I -II) and 90.0% in late stage (stage III-IV). Conclusion In summary, this study provides an efficient and non-invasive method to detect lymphoid neoplasm. Instead of relying only on one dimension of cancer markers, the multidimensional approach which incorporating CNA, fragment size and protein markers is plausible in early detection of lymphoid neoplasm with sufficient accuracy and robustness. Disclosures Zhu: Clinical Laboratories, Shenyou Bio: Current Employment. Li: SeekIn Inc.: Current Employment, Current holder of individual stocks in a privately-held company. Geng: Clinical Laboratories, Shenyou Bio: Current Employment. Chang: Clinical Laboratories, Shenyou Bio: Current Employment. Chen: SeekIn Inc: Current Employment, Current holder of individual stocks in a privately-held company. Mao: SeekIn Inc: Current Employment, Current holder of individual stocks in a privately-held company.

New mechanisms and biomarkers of lymph node metastasis in cervical cancer: reflections from plasma proteomics

Plasma-based proteomic and metabolomic characterization of lung and lymph node metastases in cervical cancer patients

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Lymphatic Metastasis-associated Biomarkers for Cancers

Identification and Experimental Validation of Immune-Associate Lncrnas for Predicting Prognosis in Cervical Cancer

Exosomal Let-7D-3p and Mir-30D-5p As Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors

Comprehensive analysis of lymph nodes metastasis associated genes in cervical cancer and its significance in treatment and prognosis

Plasma proteometabolome in lung cancer: exploring biomarkers through bidirectional Mendelian randomization and colocalization analysis

Single-cell and whole-transcriptome sequencing of lymph node metastasis-related gene signature: A large-scale pan-cancer cohort, machine learning and experimental study

Exosomes deep sequencing identifies miR-363-5p as a non-invasive biomarker of axillary lymph node metastasis and prognosis in breast cancer

Plasma CADM1 Promoter Hypermethylation and D-dimer As Novel Metastasis Predictors of Cervical Cancer.

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer

Integrating Circulating Tumor DNA Features and Plasma Protein Markers to Detected Early Lymphoid Neoplasm

Exploration of potential novel drug targets and biomarkers for small cell lung cancer by plasma proteome screening

Identification of metastasis-related long non-coding RNAs in lung cancer through a novel tumor mesenchymal score

Novel Biomarkers for Lymph Node Metastasis and Prognosis of Bladder Cancer by Bioinformatics Analysis

Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging

Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer